Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AGA receives CE Mark approval for occlusion device
The ADO II is a self-expanding nitinol mesh device and is designed to be introduced in a minimally invasive fashion through a catheter. The ADO II expands the
The ADO II is a self-expanding nitinol mesh device and is designed to be introduced in a minimally invasive fashion through a catheter. The ADO II expands the
The registry will enroll up to 2,500 patients with simple and complex lesions at multiple sites in several European countries. Of the patients at each site, half will
All of the infection control company’s safety and standard syringe products are available to Yankee Alliance members including the InviroSNAP with InviroSTRIPE, featuring a patented, integral write-on stripe
Oritavancin would be indicated for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The oritavancin NDA submission
The patient was treated with the Cook Zenith Dissection Endovascular System, which is comprised of the new Cook Zenith Dissection Stent, used in conjunction with the Cook Zenith
Sentry will warehouse and distribute more than 500,000 vaccine doses from its pharmaceutical cold chain logistics center. Ensuring product integrity, supply chain security and fast, efficient distribution is
Under terms of the agreement, Schering-Plough will reimburse OraSure for certain development costs and will provide payments to OraSure based on the achievement of certain regulatory and commercial
The series B financing was co-led by Advanced Technology Ventures and IDG Ventures Boston and included participation from series A investor, MedVenture Associates and new investor Harris &
The offer price represents a premium of approximately 39% over Possis Medical’s average closing price for the thirty days prior to February 8, 2008. The board of directors
To date, 607 patients have been enrolled in the study at more than 130 clinical trial sites in 23 countries. Total enrollment in this event-driven trial is targeted